ARTICLE | Clinical News

CVT-1: Began Phase II trial in 200 people who will be given an American Heart Association-recommended diet for six to eight weeks to stabilize their cholesterol

February 13, 1995 8:00 AM UTC

CV Therapeutics, Palo Alto Product: CVT-1, a sulfated polysaccharide that blocks cholesterol absorption from the gut through a specific receptor interaction; it is not itself absorbed into the bloodst...